Page 4 - Fusn Jue News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Fusn jue. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Fusn Jue Today - Breaking & Trending Today

Fusion Pharmaceuticals (NASDAQ:FUSN) Lifted to Strong-Buy at Raymond James

Fusion Pharmaceuticals (NASDAQ:FUSN – Get Free Report) was upgraded by analysts at Raymond James from an “outperform” rating to a “strong-buy” rating in a research note issued on Wednesday, Marketbeat reports. The brokerage presently has a $15.00 price target on the stock, up from their previous price target of $12.00. Raymond James’ price target indicates […] ....

United States , Raymond Jame , Raymond James , Sphera Funds Management , News Ratings For Fusion Pharmaceuticals Daily , Fusion Pharmaceuticals Stock Performance , Royal Bank , Analyst Recommendations For Fusion Pharmaceuticals , Fusion Pharmaceuticals Inc , Forefront Analytics , Fusion Pharmaceuticals Company Profile , Eagle Health Investments , Fusion Pharmaceuticals , Institutional Investors Weigh In On Fusion Pharmaceuticals , Hermes Inc , Get Free Report , Partners Management , Funds Management , Pharmaceuticals Inc , Fusion Pharmaceuticals Daily , Nasdaq Fusn ,

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Receives Consensus Recommendation of "Buy" from Brokerages

Shares of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN – Get Free Report) have been assigned a consensus rating of “Buy” from the seven ratings firms that are presently covering the firm, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokers that have covered the […] ....

United States , Raymond James , Millennium Management , Fusion Pharmaceuticals , Citadel Advisors , Analyst Recommendations For Fusion Pharmaceuticals , Renaissance Technologies , Hedge Funds Weigh In On Fusion Pharmaceuticals , Fusion Pharmaceuticals Stock , Hermes Inc , Fusion Pharmaceuticals Inc , News Ratings For Fusion Pharmaceuticals Daily , Fusion Pharmaceuticals Company Profile , Get Free Report , Marketbeat Ratings , Get Free , Pharmaceuticals Inc , Fusion Pharmaceuticals Daily , Nasdaq Fusn ,

Oppenheimer Initiates Coverage on Fusion Pharmaceuticals (NASDAQ:FUSN)

Oppenheimer assumed coverage on shares of Fusion Pharmaceuticals (NASDAQ:FUSN – Free Report) in a research note published on Thursday, MarketBeat Ratings reports. The firm issued an outperform rating and a $13.00 price target on the stock. Separately, Raymond James cut their price objective on shares of Fusion Pharmaceuticals from $13.00 to $12.00 and set an […] ....

United States , Raymond James , Hermes Inc , Perceptive Advisors , Institutional Trading Of Fusion Pharmaceuticals , Sphera Funds Management , Fusion Pharmaceuticals Company Profile , Analyst Recommendations For Fusion Pharmaceuticals , News Ratings For Fusion Pharmaceuticals Daily , Fusion Pharmaceuticals , Fusion Pharmaceuticals Trading Down , Fusion Pharmaceuticals Inc , Free Report , Marketbeat Ratings , Pharmaceuticals Trading Down , Get Free Report , Pharmaceuticals Inc , Fusion Pharmaceuticals Daily , Nasdaq Fusn , Initiated Coverage , Oppenheimer Holdings Inc ,